-
Iran hits back at Trump after insists truce over
-
Thousands shelter in Taiwan as typhoon lashes Japan islands
-
Scaloni wants 'never-say-die' legacy for Argentina
-
New Zealand, India form 'strategic partnership'
-
Scaloni wants Argentina's legacy to be 'never say die'
-
Courtois 'proud' as sun sets on Belgium's 'Golden Generation'
-
Spain into World Cup semi-final with France after late strike against Belgium
-
Economic uncertainty looms over Venezuela quake zone
-
Boeing unveils new 737 MAX production line as aviation giant charts comeback
-
'Beast' Haaland a different player to me, says Kane
-
Wemby inks Spurs extension, tells fans 'I'm here to stay'
-
My goals don't matter if we win World Cup, says Yamal
-
Courtois backs Lammens to bounce back after World Cup blunder
-
Spain's Merino living 'wildest dreams' with late World Cup winners
-
NBA T-Wolves add Ball and Green as James eyes options
-
Apple sues OpenAI for stealing trade secrets
-
England's Rice, Guehi and James train ahead of Norway World Cup clash
-
Spain set up World Cup semi-final with France after late win against Belgium
-
Merino strikes late as Spain beat Belgium to set up France World Cup semi
-
Alfred trumps Thomas in battle of Olympic sprint champions
-
Ohtani to miss All-Star Game for treatment on knee
-
Brutal heat wave forecast for western US this weekend
-
Hundreds of Peruvian newborns named after Norway striker Haaland
-
Music industry launches AI-generated content labels
-
Wall Street gets small boost from SK hynix debut
-
SK hynix surges on first day of trading on Wall Street
-
Deschamps leads France to familiar territory in final World Cup
-
Edwards leaves role with Liverpool owners FSG
-
Alfred goes third in 200m all-time list, Wanyonyi smashes 1km mark
-
Wemby to Spurs fans: 'I'm here to stay, whatever it takes'
-
Trump agrees to more Iran talks but insists truce is over
-
Trump administration weakens habitat protections for endangered species
-
'No secret' that Kane v Haaland the key to England clash, says Norway coach Solbakken
-
Scheffler misses first cut in four years as McIlroy leads at Scottish Open
-
Prince Harry and family meet King Charles: UK media
-
Nearly 50 abducted pupils, teachers rescued in Nigeria
-
Sinner salutes 'true inspiration' Djokovic after ending rival's Wimbledon bid
-
Wanyonyi sets new world best in men's 1,000m
-
US senators announce Trump deal on Russia sanctions bill
-
Djokovic expects to be back at Wimbledon next year
-
Foreigners among 12 killed in ferocious Spain wildfire
-
Sinner, Zverev power into Wimbledon final
-
Vinicius apologizes to Brazilians for World Cup 'frustration'
-
Trump says agreed to more Iran talks but insists truce over
-
Slick Sinner scuppers Djokovic record bid to make Wimbledon final
-
Zverev hungry for Wimbledon glory after Paris breakthrough
-
India's Mandhana stars in inaugural women's Test at Lord's
-
England risk losing Guehi for Norway World Cup quarter-final
-
Xhaka tells Swiss fans to 'keep dreaming' ahead of Argentina World Cup clash
-
UK police launch murder probe into ex-MP's death
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").
D. Boral Capital LLC acted as the Exclusive Placement Agent for the Offering.
The shares of common stock were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on April 24, 2026.
A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC. Once filed, it was available on the SEC's website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL(TM) -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia (TM), a consumer longevity supplement. The acquisition of ALA-002 U.S. rights further strengthens the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.
About D. Boral Capital
D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.
A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately $35 billion in capital since its inception in 2020, executing ~400 transactions across a broad range of investment banking products.
D. Boral Capital is a member of FINRA and SIPC.
Forward-Looking Statements
Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K filed on April 1, 2026. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For more information, please contact:
Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
[email protected]
D. Boral Capital LLC
Email: [email protected]
Telephone: +1 (212) 970-5150
SOURCE: D. Boral Capital
View the original press release on ACCESS Newswire
D.Moore--AMWN